M&T Bank Corp Has $321.16 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

M&T Bank Corp increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15,705.6% during the 4th quarter, Holdings Channel reports. The firm owned 3,571,595 shares of the medical equipment provider’s stock after purchasing an additional 3,548,998 shares during the quarter. Zimmer Biomet makes up approximately 1.0% of M&T Bank Corp’s holdings, making the stock its 16th largest holding. M&T Bank Corp’s holdings in Zimmer Biomet were worth $321,158,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rakuten Investment Management Inc. purchased a new position in Zimmer Biomet during the third quarter worth about $37,307,000. Sector Gamma AS boosted its holdings in Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after purchasing an additional 24,847 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after purchasing an additional 13,812 shares during the last quarter. Border to Coast Pensions Partnership Ltd boosted its holdings in Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after purchasing an additional 22,104 shares during the last quarter. Finally, National Pension Service boosted its holdings in Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after purchasing an additional 16,928 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $92.78 on Wednesday. The stock has a market capitalization of $17.96 billion, a P/E ratio of 26.21, a PEG ratio of 1.95 and a beta of 0.61. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average is $93.80 and its 200 day moving average is $93.15. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same period last year, the company earned $2.31 earnings per share. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.39 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. William Blair initiated coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Sanford C. Bernstein lifted their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Finally, UBS Group reaffirmed a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average target price of $105.95.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.